European Commission approves belimumab in combination with background immunosuppressive therapies for adults with active lupus nephritis

The license extension was based on data from the BLISS-LN study, which showed that the addition of belimumab to standard therapy increased Primary Efficacy Renal Response rate at 104 weeks (43% vs 32% with placebo).

Source:

PharmaTimes